Glycoprotein / GP (virus)

Glycoprotein / GP (virus) Molekülinformation

Englischer Name	Envelope glycoprotein	Anzahl der inverkehr gebrachten Arzneimittel	2
Anzahl der klinischen Arzneimittel	2	Target-Alias	GP1，2，GP，Envelope glycoprotein
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Envelope glycoprotein
Target-Alias	GP1，2，GP，Envelope glycoprotein
Anzahl der inverkehr gebrachten Arzneimittel	2
Anzahl der klinischen Arzneimittel	2
Höchste Forschungs- und Entwicklungsphase	Approved

Produktanfrage

Glycoprotein / GP (virus) Molekülhintergrund

EBOV encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA polymerase (L). GP protein contains 160-kDa envelope-attached glycoprotein (GP) and a 110 kDa secreted glycoprotein (sGP). GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . GP1 is responsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into the host cell. GP2 acts as a class I viral fusion protein. GP1,2 mediates endothelial cell activation and decreases endothelial barrier function. sGP seems to possess an anti-inflammatory activity as it can reverse the barrier-decreasing effects of TNF alpha.

Glycoprotein / GP (virus) Molekülalias

GP,Envelope glycoprotein,GP(1,2)

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Porgaviximab/Larcaviximab/Cosfroviximab	c2G4-N; c4G7; c13C6	Phase 3 Clinical	Mapp Biopharmaceutical, Public Health Agency Of Canada'S National Microbiology Laboratory	Hemorrhagic Fever, Ebola	Details
MIL-77	MIL-77	Phase 1 Clinical	Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Institute Of Basic Medicine Academy Of Military Medical Sciences	Hemorrhagic Fever, Ebola	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Ansuvimab	VRC-EBOMAB092-00-AB; MAb114; MAb-114	Approved	National Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, Islamabad	Ebanga	United States	Hemorrhagic Fever, Ebola	Ridgeback Biotherapeutics Lp	2020-12-21	Hemorrhagic Fever, Ebola	Details
Atoltivimab/Maftivimab/Odesivimab	REGN3470-3471-3479; REGN-EB3	Approved	Regeneron Pharmaceuticals Inc	Inmazeb	United States	Hemorrhagic Fever, Ebola	Regeneron Pharmaceuticals Inc	2020-10-14	Hemorrhagic Fever, Ebola	Details